NCT02524197 - A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Osteoarthritis

Interventions

DRUG

CR845 0.25 mg

Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.

DRUG

CR845 0.50 mg

Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.

DRUG

CR845 1 mg

Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.

DRUG

CR845 5 mg

Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.

Trial Locations (5)

16635

Altoona Center for Clinical Research, Duncansville

27410

Triad Clinical Trials, LLC, Greensboro

68134

Heartland Clinical Research, Omaha

75075

Clinical Investgations of Texas, Plano

Unknown

Matthew Barton, MD, Las Vegas